Today I came across some news that I wanted to share with you all. A month or two ago I wrote about the new drug Forxiga that was approved for use in diabetics in the European Union. Since then, we have had much interest on the blog about Forxiga, which has been introduced to the US as Farxiga, and many have wondered when a drug like this will be available in the US. Well today I found out that we might be close to that day.
An advisory panel for the Food and Drug Administration (FDA) has just recently recommended that the FDA approve a new drug that works like Forxiga. If you remember, the FDA is the group that decides whether a drug is safe and effective, and whether or not it can be sold in the US. This new drug would be called Invokana and marketed by Johnson and Johnson. In reading up on Invokana, I found out that it works the same way as Forxiga.
Invokana helps your body get rid of sugar (glucose) through your urine. If it is approved, this will be the first medication that works like this in the United States. There are a few concerns about Invokana that need to be addressed though. First, Invokana might not work as well in patients with kidney problems. Also, within the first 30 days of starting the medication, some patients had heart problems and strokes. And, Invokana seemed to slightly raise bad cholesterol levels in some patients (although it did raise good cholesterol levels as well). These are things that the FDA and Johnson and Johnson will have to address before the medication is approved. It is anticipated that we will know around the end of March 2013 whether or not Invokana will be sold in the United States. If it is, I will do a full write-up on the medication at that time.
If you would like to read more about Invokana, here are a few links:
An FDA advisory panel backed a proposed Johnson & Johnson diabetes drug despite concerns about potential cardiovascular risks and less benefit in patients with impaired kidneys.
A federal advisory panel has voted 10-5 to approve a diabetes drug that could be the first in a new class of drugs in the United States to treat the disease, although several members raised concerns about potential cardiovascular risks and its use in people whose kidneys are impaired.
As a disclaimer, I am your “virtual” pharmacist, here to provide you with information and answers to questions. However, I am not your local pharmacist and could, in no way, be aware of your specific medical needs. Remember to always check with your medical provider and pharmacist before stopping or starting any new medications. My posts are based on general pharmacy principles and should not considered as your “first opinion” when it comes to your health. Please consult with your doctor and pharmacist about anything regarding your health.